Management ChangeJun 10, 2026, 04:23 PM
LB Pharmaceuticals CMO Anna Eramo Resigns, Transitions to Advisor
AI Summary
LB Pharmaceuticals Inc. announced that Anna Eramo, M.D., resigned from her position as Chief Medical Officer, effective June 15, 2026, for personal reasons. Dr. Eramo will transition to an advisor role on June 16, 2026, and will provide full-time consulting services until September 15, 2026. The company stated that her departure is not related to clinical program operations and is not expected to materially impact clinical development activities or milestones. In connection with her resignation, Dr. Eramo entered into a separation and consulting agreement, which includes continued base salary, a prorated 2026 annual bonus, accelerated vesting of 66,143 stock options, and COBRA reimbursement.
Key Highlights
- Anna Eramo resigned as Chief Medical Officer of LB Pharmaceuticals, effective June 15, 2026.
- She will transition to an advisor role on June 16, 2026, providing full-time consulting until September 15, 2026.
- Her departure is for personal reasons and not expected to materially impact clinical development activities.
- A search is underway for her replacement.
- She will receive her current base salary monthly until June 15, 2027.
- She is entitled to 100% of her prorated 2026 target annual bonus.
- 66,143 unvested stock options will accelerate and vest on September 15, 2026.
- COBRA healthcare premium costs will be reimbursed for up to 12 months following the separation date.
Price Impact
More from LBRX